07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Avac Pharma Ltd., ChronTech deal

ChronTech said newco Avac completed its acquisition of all of ChronTech's assets related to development programs for DNA vaccines against HBV and HCV. ChronTech could not be reached for details (see BioCentury, May 13 &...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

ChronTech infectious, drug delivery news

At its May 16 meeting, ChronTech's shareholders approved the transfer of all of the company's assets related to development programs for DNA vaccines against HBV and HCV to newco Avac Pharma Ltd. for $1 million....
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

ChronTech infectious, drug delivery news

ChronTech said that a group of shareholders offered to acquire all assets related to ChronTech's development programs for DNA vaccines against HBV and HCV for $1 million. The shareholders have formed newco Avac Pharma Ltd....
07:00 , Apr 14, 2008 |  BC Week In Review  |  Company News

SemBioSys, Avac Ltd. deal

Under a 2006 deal to develop SemBioSys' safflower-produced insulin program, SemBioSys received a $350,000 milestone payment from Avac for completing technical objectives, including starting a preclinical toxicology study. The company has now received $873,000 in...
07:00 , Mar 31, 2008 |  BioCentury  |  Finance

Ebb & Flow

VaxGen and oncology company Raven caved under the weight of shareholder disapproval last week and terminated their merger plans. The deal had been scheduled for a shareholder vote on Friday, but was pulled due to...
08:00 , Jan 3, 2005 |  BC Week In Review  |  Company News

SemBioSys, Avac Ltd. deal

SBS received $229,000 from Avac for reaching a third milestone in a deal to develop the StratoCapture Protein A Purification System. The milestone brings total payments to SBS to $1.4 million. SBS will use the...
07:00 , Sep 15, 2003 |  BC Week In Review  |  Clinical News

AVAC: Phase II

GEN and SPA started a placebo-controlled New Zealand Phase II trial in 120 children ages 5-16. Genesis Research and Development Corp. (ASX:GEN), Auckland, New Zealand   SR Pharma plc (LSE:SPA), London, U.K.   Product: AVAC...
07:00 , Sep 10, 2003 |  BC Extra  |  Clinical News

Genesis, SR Pharma start Phase II eczema trial

Genesis Research (ASE:GEN) and SR Pharma (LSE:SPA) started a placebo-controlled New Zealand Phase II trial of AVAC to treat pediatric atopic dermatitis in 120 children ages 5-16. The primary endpoint is efficacy as measured by...
07:00 , Jun 30, 2003 |  BC Week In Review  |  Clinical News

SRP299: Phase I

SPA completed enrollment of 145 patients in a European Phase II trial. GEN and SPA are co-developing SRP299. Genesis Research and Development Corp. (ASX:GEN), Auckland, New Zealand   SR Pharma plc (LSE:SPA), London, U.K.  ...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Clinical News

AVAC: Phase I

In a New Zealand Phase I trial in 12 patients, 3 intradermal injections of AVAC at 2 week intervals was safe and well tolerated. Genesis Research and Development Corp. (NZSE/ASX:GEN), Auckland, New Zealand   SR...